Open Access. Powered by Scholars. Published by Universities.®
Medicinal-Pharmaceutical Chemistry Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Alzheimer’s disease (1)
- Amines (1)
- Antitumor activity (1)
- Atherosclerosis (1)
- Cancer (1)
-
- Catalysis (1)
- Cell culture (1)
- Cells (1)
- Copper (1)
- Crystallography (1)
- Diabetes (1)
- Diseases (1)
- Interaction energy (1)
- Intramolecular amination (1)
- LXRα (1)
- LXRβ specific ligands (1)
- Lipid metabolism (1)
- Liver X receptors (1)
- Molecular modeling (1)
- N-iodosuccinimide (1)
- N-triazol-5-yl-oxazolidin-4-one (1)
- Nitrogen compounds (1)
- Salts (1)
- Single crystals (1)
- X ray crystallography (1)
Articles 1 - 3 of 3
Full-Text Articles in Medicinal-Pharmaceutical Chemistry
Synthesis And Antitumor Activity Of N-Triazol-5-Yl-Oxazolidin-4-One Derivatives., R. Luo, S. Guo, Shilong Zheng, Guangdi Wang, X. Bao, L. He
Synthesis And Antitumor Activity Of N-Triazol-5-Yl-Oxazolidin-4-One Derivatives., R. Luo, S. Guo, Shilong Zheng, Guangdi Wang, X. Bao, L. He
Faculty and Staff Publications
Fifteen novel N-triazol-5-yl-oxazolidin-4-ones were synthesized through a few of steps from the benzaldehydes. It was found that N-iodosuccinimide (NIS) can promote intramolecular amination reaction which is the key step of the syntheses, which will be used as new method for the intramolecular formation of nitrogen-containing heterocycles. Part of the compounds were evaluated for their anticancer activity. Among them, compounds 6a, 6b and 6c showed moderate antiprolifiration activity toward human breast cancer cells MDA-MB-231 cell lines, while the mild activity of 6a, 6b and 6d against human cervical cancer HeLa cell lines was confirmed in vitro assay.
Ligands Of Therapeutic Utility For The Liver X Receptors., Rajesh Komati, Dominick Spadoni, Shilong Zheng, Jayalakshmi Sridhar
Ligands Of Therapeutic Utility For The Liver X Receptors., Rajesh Komati, Dominick Spadoni, Shilong Zheng, Jayalakshmi Sridhar
Faculty and Staff Publications
Liver X receptors (LXRs) have been increasingly recognized as a potential therapeutic target to treat pathological conditions ranging from vascular and metabolic diseases, neurological degeneration, to cancers that are driven by lipid metabolism. Amidst intensifying efforts to discover ligands that act through LXRs to achieve the sought-after pharmacological outcomes, several lead compounds are already being tested in clinical trials for a variety of disease interventions. While more potent and selective LXR ligands continue to emerge from screening of small molecule libraries, rational design, and empirical medicinal chemistry approaches, challenges remain in minimizing undesirable effects of LXR activation on lipid metabolism. …
Copper Salt-Catalyzed Formation Of A Novel Series Of Triazole-Spirodienone Conjugates With Potent Anticancer Activity., L. Gu, P. Wang, Qiu Zhong, Y. Deng, J. Xie, F. Liu, F. Xiao, Shilong Zheng, Y. Chen, Guangdi Wang, L. He
Copper Salt-Catalyzed Formation Of A Novel Series Of Triazole-Spirodienone Conjugates With Potent Anticancer Activity., L. Gu, P. Wang, Qiu Zhong, Y. Deng, J. Xie, F. Liu, F. Xiao, Shilong Zheng, Y. Chen, Guangdi Wang, L. He
Faculty and Staff Publications
Copper salt-catalyzed oxidative amination resulted in the formation of a novel series of triazole-spirodienone conjugates, 4-triazolyl-1-oxa-4-azaspiro[4,5]deca-6,9-dien-3,8-diones and 4-triazolyl-1-oxa-4-azaspiro[4,5]deca-6,9-dien-8-ones. A single crystal of compound 1p among them was grown and analyzed by X-ray crystallography. These compounds were evaluated for their antiproliferative activities against MDA-MB-231, HeLa, A549 and MCF-7 cell lines. Most of them showed moderate to high anticancer potency in the four cancer cell lines. The discovery of the triazole-spirodienone conjugates as cytotoxic agents against cancer cells may open up a new field in which these novel small molecules could be further explored as promising anticancer agents.